Why the study?
Heart failure remains associated with significant morbidity and mortality, likely contributed to by difficulty in titrating doses of targeted drugs, raising the question of guiding treatment based on natriuretic peptide levels.
Does heart failure therapy guided by natriuretic peptide levels reduce mortality and hospitalizations in patients with heart failure?
Does heart failure therapy guided by natriuretic peptide levels reduce mortality and hospitalizations in patients with heart failure?
Current evidence does not support the routine use of natriuretic peptide levels as a standalone strategy to guide heart failure treatment titration due to conflicting trial results.
Answers are grounded in this paper and cite their sources.
Natriuretic peptide-guided HF titration remains unresolved; leaves open whether biomarker-directed dosing improves outcomes in practice.
Heart failure (HF) is one of the leading causes of death, hospitalization, and rehospitalization worldwide. In spite of advances in treatment with new medications, devices, and heart transplantation, the condition is still associated with significant morbidity and mortality.1 One factor that likely contributes to this fact is the difficulty in titrating doses of drugs targeted at treating HF.2 […] Treatment of Heart Failure Based on Natriuretic Peptide Levels: A Question That Has Yet to be Solved?
No takes yet. Share an insight, caveat, or question.
Montenegro et al. (2022) conducted a review in Heart Failure. Natriuretic peptide-guided therapy vs. Symptom-guided or conventional therapy was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: